Kura Oncology, Inc. (KURA) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $11.10: Quality below floor (2.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 9.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Below-average business quality.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1... Read more
Sell if holding. Engine safety override at $11.10: Quality below floor (2.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 9.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.3/10, moderate confidence.
Passes 7/7 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 33d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Recent developments
updated 2026-07-05Recent Developments — Kura Oncology, Inc.
Latest news
- NEWS Kura Oncology Reports Q1 2026 Results: Full Earnings Call Transcript — benzinga Jul 2, 2026 neutral
Generated 2026-07-05T10:00:59Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $11.10: Quality below floor (2.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 9.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $10.32. Score 5.3/10, moderate confidence.
Take-profit target: $27.12 (+144.3% upside). Prior stop was $10.32. Stop-loss: $10.32.
Quality below floor (2.4 < 4.0); Value-trap signals (2/5): Revenue declining (-91.4% YoY), Margin compression (op margin -982.9%).
Kura Oncology, Inc. trades at a P/E of N/A (forward -4.3). TrendMatrix value score: 5.8/10. Verdict: Sell.
22 analysts cover KURA with a consensus score of 4.1/5. Average price target: $31.
What does Kura Oncology, Inc. do?Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The...
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.